Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Increasing Complexity
Posted on July 5, 2018
Thorsten Lorenz, PhD, Head Developability Assessment
Thomas Jostock, PhD, Science and Technology Lead
Paul Wassmann, PhD, Analytical Technology and Strategy Lead
Philipp Amsler, Functional Lead Downstream Processing
Steffen Hartmann, PhD, Global Head Integrated Biologics Profiling
Novartis Pharma AG, Technical Development New Biologics Entities – Integrated Biologics Profiling, Klybeckstrasse 141, 4057 Basel, Switzerland
Introduction Over the last decades, biopharmaceuticals have become of growing importance to address unmet medical needs. Seven out of the 10 top selling pharmaceutical products are biopharmaceuticals covering a breadth of disease areas and patient populations1. To reduce the risk of high costs and p...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
developability assessment, integrated biologics profiling, process development, therapeutic proteins, toolbox approach
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
